The role of human CYP 2 C 8 and CYP 2 C 9 variants in pioglitazone metabolism in vitro

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Trimethoprim and the CYP2C8*3 Allele Have Opposite Effects on the Pharmacokinetics of Pioglitazone

  2008cited by this paper
• Prediction of the metabolic interaction of nateglinide with other drugs based on in vitro studies.

  2007cited by this paper
• High-performance liquid chromatography analysis of CYP2C8-catalyzed paclitaxel 6alpha-hydroxylation.

  2006cited by this paper
• Pioglitazone is metabolised by CYP2C8 and CYP3A4 in vitro: potential for interactions with CYP2C8 inhibitors.

  2006influential reference
• Pharmacokinetics and pharmacodynamics of rosiglitazone in relation to CYP2C8 genotype

  2006cited by this paper
• Pioglitazone, an in vitro inhibitor of CYP2C8 and CYP3A4, does not increase the plasma concentrations of the CYP2C8 and CYP3A4 substrate repaglinide

  2006cited by this paper
• The impact of CYP2C8 polymorphism and grapefruit juice on the pharmacokinetics of repaglinide.

  2006cited by this paper
• Effects of Gemfibrozil, Itraconazole, and Their Combination on the Pharmacokinetics of Pioglitazone

  2005influential reference
• Polymorphic Organic Anion Transporting Polypeptide 1B1 is a Major Determinant of Repaglinide Pharmacokinetics

  2005cited by this paper
• Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 Polymorphisms with the Pharmacokinetics of Paclitaxel

  2005cited by this paper
• The effect of the cytochrome P450 CYP2C8 polymorphism on the disposition of (R)-ibuprofen enantiomer in healthy subjects.

  2005cited by this paper
• Effect of Genetic Polymorphisms in Cytochrome P450 (CYP) 2C9 and CYP2C8 on the Pharmacokinetics of Oral Antidiabetic Drugs

  2005cited by this paper
• Influence of CYP2C9 and CYP2D6 Polymorphisms on the Pharmacokinetics of Nateglinide in Genotyped Healthy Volunteers

  2004cited by this paper
• Thiazolidinediones, peripheral edema, and type 2 diabetes: incidence, pathophysiology, and clinical implications.

  2003cited by this paper
• Rosiglitazone and pulmonary oedema: an acute dose-dependent effect on human endothelial cell permeability

  2003cited by this paper
• Comparative effects of thiazolidinediones on in vitro P450 enzyme induction and inhibition.

  2003cited by this paper
• Polymorphism in CYP2C8 is associated with reduced plasma concentrations of repaglinide

  2003cited by this paper
• Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms.

  2002influential reference
• Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid.

  2001influential reference
• Cytochrome P450 metabolites of arachidonic acid: novel regulators of renal function.

  2001cited by this paper
• Clinical pharmacokinetics of pioglitazone

  2000cited by this paper
• In vitro inhibitory effects of troglitazone and its metabolites on drug oxidation activities of human cytochrome P450 enzymes: comparison with pioglitazone and rosiglitazone.

  2000cited by this paper
• Estimation of cytochrome P-450 CYP1A2 activity in 863 healthy Caucasians using a saliva-based caffeine test.

  1999cited by this paper
• Inhibitory effects of trospium chloride on cytochrome P450 enzymes in human liver microsomes.

  1999cited by this paper
• Cytochrome P450, the arachidonic acid cascade, and hypertension: new vistas for an old enzyme system

  1996cited by this paper

• Influence of CYP2C8*2 on the Pharmacokinetics of Pioglitazone in Healthy African‐American Volunteers

  2013cites this paper